PF-08046040

Unknown / undisclosed

CD70No recent registered activity

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no market stage

Evidence outlook

Studies registered, no market-specific stage

Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT02216890 · Seagen Inc.
2014-08 – 2017-02-15 · Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3
What this study did

Competitive landscape

2 other tracked programmes target this mechanism.

This drug's own stage for Myelodysplastic Syndromes: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PF-08046040: this drugStage not on recordUndisclosedCD70not yet gradedNo reviewed efficacy summary in this indication
AzacitidineApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Imetelstat (Rytelo)ApprovedRNA / oligonucleotideTelomeraseReliable signalNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
ElriterceptPhase 3UndisclosedActivin A/Bnot yet gradedNo reviewed efficacy summary in this indication
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
AND017Phase 2Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
Cusatuzumab
Phase 2(overall)
Monoclonal antibodyCD70
Weak signal(overall)
No reviewed efficacy summary in this indication
MomelotinibPhase 2Small moleculeJAK1 / JAK2 / ACVR1not yet gradedNo reviewed efficacy summary in this indication
R289Phase 1/2Small moleculeIRAK1/IRAK4not yet gradedNo reviewed efficacy summary in this indication
REGN17235
—(overall)
Multispecific antibodySLC3A2 x CD3not yet gradedNo reviewed efficacy summary in this indication
CTX131
Discontinued
Cell therapyCD70
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.